Cargando…

Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis

Detalles Bibliográficos
Autores principales:	Yousef, Zaheer, Elliott, Perry M., Cecchi, Franco, Escoubet, Brigitte, Linhart, Ales, Monserrat, Lorenzo, Namdar, Mehdi, Weidemann, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596758/ https://www.ncbi.nlm.nih.gov/pubmed/22736678 http://dx.doi.org/10.1093/eurheartj/ehs166

Ejemplares similares

Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy
por: Kim, Woo-Shik, et al.
Publicado: (2019)

Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy
por: Sadasivan, Chandu, et al.
Publicado: (2020)

Mono-symptomatic Fabry disease in a population with mild-to-moderate left ventricular hypertrophy
por: Fuller, Maria, et al.
Publicado: (2020)

Does a Hypertrophying Muscle Fibre Reprogramme its Metabolism Similar to a Cancer Cell?
por: Wackerhage, Henning, et al.
Publicado: (2022)

Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis
por: Corrado, Domenico, et al.
Publicado: (2020)

The distribution of hypertrophy in anderson fabry disease
por: Sado, Daniel M, et al.
Publicado: (2011)

Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
por: Baptista, Ana, et al.
Publicado: (2015)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement
por: Corrado, Domenico, et al.
Publicado: (2015)

Ascending aorta dilatation common feature which correlate with left ventricular hypertrophy in fabry disease
por: Bensalah, Mourad, et al.
Publicado: (2011)

Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy
por: Krämer, Johannes, et al.
Publicado: (2015)

Electrocardiographic Changes and Arrhythmia in Fabry Disease
por: Namdar, Mehdi
Publicado: (2016)

Big shoes to fill: Timothy Fabian, inaugural editor of Trauma Surgery & Acute Care Open (TSACO)
por: Haut, Elliott R
Publicado: (2023)

Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation
por: Packer, Milton
Publicado: (2019)

Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study in Turkey
por: Barman, Hasan Ali, et al.
Publicado: (2020)

Three-dimensional echocardiographic left ventricular strain analysis in Fabry disease: correlation with heart failure severity, myocardial scar, and impact on long-term prognosis
por: Marek, Josef, et al.
Publicado: (2023)

Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation
por: Chien, Yueh, et al.
Publicado: (2016)

Left Ventricular Torsion Associated With Aortic Stiffness in Hypertension
por: Gnakamene, Jean‐Barthelemy, et al.
Publicado: (2018)

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
por: Augusto, João B, et al.
Publicado: (2020)

Methodological Considerations for Studies in Sport and Exercise Science with Women as Participants: A Working Guide for Standards of Practice for Research on Women
por: Elliott-Sale, Kirsty J., et al.
Publicado: (2021)

Unexplained Left Ventricular Hypertrophy Diagnosed as a Cardiac Variant of Late-Onset Fabry Disease: A Case Report
por: Zhao, Maomao, et al.
Publicado: (2023)

Understanding Training Load as Exposure and Dose
por: Impellizzeri, Franco M., et al.
Publicado: (2023)

Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease
por: Graziani, Francesca, et al.
Publicado: (2020)

Longitudinal strain bull’s eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy
por: Liu, Dan, et al.
Publicado: (2016)

Moexipril and left ventricular hypertrophy
por: Chrysant, George S, et al.
Publicado: (2007)

Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013)

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts
por: Germain, Dominique P., et al.
Publicado: (2019)

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

ERT impact on left ventricular mass in Fabry disease
por: Ortiz, Alberto
Publicado: (2019)

Obstructive sleep apnea and left ventricular strain: Useful tool or fancy gadget?
por: Cuspidi, Cesare, et al.
Publicado: (2019)

Mining the Mesenchymal Stromal Cell Secretome in Patients with Chronic Left Ventricular Dysfunction
por: Morrissey, Jacquelynn, et al.
Publicado: (2022)

Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease
por: Rob, Daniel, et al.
Publicado: (2016)

Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization
por: Sharman, James E., et al.
Publicado: (2017)

Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease
por: Fujii, Hideki, et al.
Publicado: (2012)

Myocardial Energetics in Left Ventricular Hypertrophy
por: Jameel, Mohammad N, et al.
Publicado: (2009)

Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers
por: Bacharova, Ljuba, et al.
Publicado: (2023)

Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond
por: Nowicki, Michał, et al.
Publicado: (2021)

Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease
por: Rob, Daniel, et al.
Publicado: (2017)

High Prevalence of Late-Onset Fabry Cardiomyopathy in a Cohort of 499 Non-Selective Patients with Left Ventricular Hypertrophy: The Asian Fabry Cardiomyopathy High-Risk Screening Study (ASIAN-FAME)
por: Fan, Yiting, et al.
Publicado: (2021)

Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations
por: Rob, Daniel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1uj5eepr9gptg6bkpcu0pqnpc7